Quotes for SelectImmune Pharma AB (publ)
Right Now
- +/-
- %
- Latest
- High
- Low
- Volume
- Turnover ()
- Time (Latest trade)
Board
CEO
- Gabriela Godaly (tf)
Chairperson of the Board
- Catharina Svanborg
Board
- Carl-Johan Wachtmeister
- Gabriela Godaly
- Helena Lomberg
SelectImmune Pharma AB (publ)
SelectImmune Pharma is a pharmaceutical company. The company intends to develop drug candidates with focus on endogenous inflammatory agents and bacterial molecules. The products are aimed at strengthening the immune system and are mainly used for the treatment of infectious diseases, as well as chronic inflammation. The company was founded in 2017 and has the largest operations in the Nordic market.
News
- Spotlight: Market Notice 174/23 – SelectImmune Pharma AB (publ) will be delisted after close of the market on August 9, 2023
- Bolagsverket meddelar tillstånd till fusion mellan Hamlet Pharma AB (publ) och SelectImmune Pharma AB (publ)
- INTERIM REPORT JANUARY 1st 2023 – MARCH 31st 2023
- Introducing Hamlet BioPharma to investors
- Kommuniké Från Extra Bolagsstämman i SelectImmune Pharma AB
Largest Owners
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Catharina Svanborg | 45,84 | 73,33 | 2023-06-28 |
| Rolf Karlsson | 6,42 | 3,16 | 2023-06-28 |
| Avanza Pension | 3,55 | 1,75 | 2023-06-28 |
| Fredrik Herslow | 3,47 | 1,71 | 2023-06-28 |
| Jan Zetterberg | 3,24 | 1,60 | 2023-06-28 |
| Swedbank Försäkring | 1,72 | 0,84 | 2023-06-28 |
| Helena Lomberg | 1,46 | 0,72 | 2023-06-28 |
| Nordnet Pensionsförsäkring | 1,42 | 0,70 | 2023-06-28 |
| Monica Strömberg | 1,11 | 0,55 | 2023-06-28 |
| Peter Ryman | 1,02 | 0,50 | 2023-06-28 |
Insider trading
*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority
Key Numbers
*Compiled data from Millistream